Carney complex predisposes to breast cancer: prospective study of 50 women.

PRKAR1A Carney Complex breast cancer breast lesion

Journal

European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848

Informations de publication

Date de publication:
22 Jan 2024
Historique:
received: 06 11 2023
revised: 23 12 2023
accepted: 28 12 2023
medline: 22 1 2024
pubmed: 22 1 2024
entrez: 22 1 2024
Statut: aheadofprint

Résumé

Carney Complex (CNC) is a rare genetic syndrome, mostly due to germline loss-of-function pathogenic variants in PRKAR1A. CNC includes pigmented skin lesions, cardiac myxomas, primary pigmented nodular adrenocortical dysplasia, and various breast benign tumors. The present study was designed to describe the characteristics of breast lesions in CNC patients and their association with other manifestations of CNC and PRKAR1A genotype. A 3 years' follow-up multicenter French prospective study of CNC patients (ClinicalTrial.gov NCT00668291) included 50 women who were analyzed for CNC manifestations and particularly breast lesions, with breast imaging, genotyping, and hormonal settings. Among the 38 women with breast imaging, 14 (39%) had breast lesions, half of them bilateral. Ten women (26%) presented with benign lesions and six with breast carcinomas (16%): one had ductal carcinoma in situ at 54 and five had invasive cancer before 50 years old, whom one with contralateral breast cancer during follow-up. The occurrence of breast cancer was more frequent in women with PRKAR1A pathogenic variant OR=6.34[1.63-17.91] than in general population of same age. The mean age at breast cancer diagnosis was 44.7 years old:17 years younger than in the general population. Breast cancer patients had good prognosis factors. All breast carcinomas occurred in individuals with familial CNC and PRKAR1A pathogenic variants. Loss of heterozygosity at the PRKAR1A locus in the 2 invasive breast carcinomas analyzed suggested a driver role of this tumor suppressor gene. As CNC could predispose to breast carcinoma, an adequate screening strategy and follow up should be discussed in affected women.

Identifiants

pubmed: 38252880
pii: 7584982
doi: 10.1093/ejendo/lvae010
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Patricia Vaduva (P)

INSERM U1016, CNRS UMR8104, Cochin Institute, Paris Cité University, 75005 Paris.

Florian Violon (F)

INSERM U1016, CNRS UMR8104, Cochin Institute, Paris Cité University, 75005 Paris.

Anne Jouinot (A)

INSERM U1016, CNRS UMR8104, Cochin Institute, Paris Cité University, 75005 Paris.
Department of Endocrinology, Reference center for rare adrenal diseases, Cochin Hospital, APHP, 75014 Paris, France.

Lucas Bouys (L)

INSERM U1016, CNRS UMR8104, Cochin Institute, Paris Cité University, 75005 Paris.
Department of Endocrinology, Reference center for rare adrenal diseases, Cochin Hospital, APHP, 75014 Paris, France.

Stéphanie Espiard (S)

Department of Endocrinology, Diabetology, Metabolism and Nutrition, Lille University Hospital, University of Lille, Inserm 1190, 59000 Lille, France.

Fidéline Bonnet-Serrano (F)

Department of Hormonology, Cochin Hospital, APHP, 75014 Paris, France.

Marie Odile North (MO)

Department of Oncogenetics, Cochin Hospital, APHP, 75014 Paris, France.

Catherine Cardot-Bauters (C)

Department of Endocrinology, Diabetology, Metabolism and Nutrition, Lille University Hospital, University of Lille, Inserm 1190, 59000 Lille, France.

Gerald Raverot (G)

Department of Endocrinology, Groupement Hospitalier Est, Hospices Civils de Lyon, 69677 Bron, France.

Sylvie Hieronimus (S)

Department of Endocrinology, Diabetology, Reproductive medicine, Nice University Hospital, 06200 Nice, France.

Hervé Lefebvre (H)

Univ Rouen Normandie, INSERM, NORDIC UMR 1239, CHU Rouen, Department of Endocrinology, F-76000 Rouen, France.

Marie-Laure Nunes (ML)

Department of Endocrinology, Diabetology and Metabolism, Bordeaux University Hospital, 33600 Pessac, France.

Antoine Tabarin (A)

Department of Endocrinology, Diabetology and Metabolism, Bordeaux University Hospital, 33600 Pessac, France.

Lionel Groussin (L)

INSERM U1016, CNRS UMR8104, Cochin Institute, Paris Cité University, 75005 Paris.
Department of Endocrinology, Reference center for rare adrenal diseases, Cochin Hospital, APHP, 75014 Paris, France.

Guillaume Assié (G)

INSERM U1016, CNRS UMR8104, Cochin Institute, Paris Cité University, 75005 Paris.
Department of Endocrinology, Reference center for rare adrenal diseases, Cochin Hospital, APHP, 75014 Paris, France.

Mathilde Sibony (M)

Department of Pathology, Cochin Hospital, APHP, 75014 Paris, France.

Marie-Christine Vantyghem (MC)

Department of Endocrinology, Diabetology, Metabolism and Nutrition, Lille University Hospital, University of Lille, Inserm 1190, 59000 Lille, France.

Eric Pasmant (E)

Department of Oncogenetics, Cochin Hospital, APHP, 75014 Paris, France.

Jérôme Bertherat (J)

INSERM U1016, CNRS UMR8104, Cochin Institute, Paris Cité University, 75005 Paris.
Department of Endocrinology, Reference center for rare adrenal diseases, Cochin Hospital, APHP, 75014 Paris, France.

Classifications MeSH